Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM). It can lower glucose in an animal model of type 2 diabetes and shows excellent developability properties.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 17,500 | |||
2 mg | 在庫あり | ¥ 27,500 | |||
5 mg | 在庫あり | ¥ 51,000 | |||
10 mg | 在庫あり | ¥ 85,500 | |||
25 mg | 在庫あり | ¥ 144,500 | |||
50 mg | 在庫あり | ¥ 206,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 61,500 |
説明 | Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM). It can lower glucose in an animal model of type 2 diabetes and shows excellent developability properties. |
ターゲット&IC50 | ASBT:42 ± 3 nM |
別名 | GSK2330672, Iinerixibat |
分子量 | 546.68 |
分子式 | C28H38N2O7S |
CAS No. | 1345982-69-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 21.5 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Linerixibat 1345982-69-5 Microbiology/Virology HBV type-2 PBC lipid-lowering solubility nonabsorbable Inhibitor Primary diabetes GSK 2330672 Cholangitis inhibit GSK-2330672 GSK2330672 aqueous Biliary ASBT Iinerixibat inhibitor